Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis

Cartesian Therapeutics, Inc.

100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.
No CRS or ICANS observed; outpatient administration without lymphodepleting chemotherapy.
Plans to pause SLE and Descartes-15 (multiple myeloma) to prioritize MG Phase 3 and myositis.
Myositis seamless adaptive Phase 2 trial expected to start 1H26; IND filing by end 2025.
Cash runway extended to mid-2027 supporting MG Phase 3 and myositis trial initiation.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-25-000123
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2025-11-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.444672+00:00
generated_at: 2026-05-16T20:18:17.241522+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-25-000123
json_url: https://secwatch.observer/filing/0001453687-25-000123.json
markdown_url: https://secwatch.observer/filing/0001453687-25-000123.md
text_url: https://secwatch.observer/filing/0001453687-25-000123.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/0001453687-25-000123-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/rnac-20251113.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001453687-25-000123

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.